About Clinical
Research
About Clinical Trials
Have you ever wondered how new medications are developed
or how a doctor knows which medication and dosage works best?
Before a new medication is approved, it must undergo a series
of lengthy and rigorous tests, first in the laboratory, then
with animals, and ultimately in those with the disease the
medication is used to treat. Each year, billions of dollars
and millions of man hours are spent researching new methods
for the diagnosis and treatment of illnesses and diseases.
A new medication must not only be shown to be safe and effective,
but in many cases it must also demonstrate a superior benefit
when compared to similar approved drugs. Nine out of ten new
drugs fail to make it through the many phases of research
and development. For those that are successful in trials,
five or more years may elapse from the time the clinical research
process begins to the time the Food and Drug Administration
(FDA) approves the drug for use by the general public.
Is It Safe?
Clinical research studies are conducted in strict
accordance with research plans (protocols) that have been
developed by pharmaceutical companies and reviewed by the
FDA along with an Institutional Review Board (IRB) representing
the public interest. Once a study has begun, its progress
is closely monitored by each of these agencies.
Participants are evaluated frequently throughout the course
of the study to monitor effectiveness and safety of the medication.
Participants may withdraw from the study at any time, or they
may be withdrawn if the investigator feels that it is in their
best interest to do so. Upon completion of the study, patients
are usually given options for alternative treatments as the
medication under the study will often not be available for
another year or two.
Questions about safety should be directed to Sterling Institutional Review Board (SIRB) or Biomedical Institutional Review Board (BIOMED), independent review boards that provide protection for human subjects through the initial and ongoing review of research studies and the investigations and facilities that conduct them. Every clinical trial in the U.S. must be approved and monitored by an Institutional Review Board (IRB) to take note of any possible risks to study participants versus any potential benefits. An IRB by definition is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects. All institutions that conduct or support biomedical research involving people must, by federal regulation, have an IRB that initially approves and periodically reviews the research. The SIRB and BIOMED operate in compliance with the U.S. code of federal regulations, FDA regulations on human subjects research, and the International Conference on Harmonisation (ICH) guidelines.
Or visit the office for Human Research Protections Website at:
OHRP
|